• Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
• Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
• Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
• The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://ibn.fm/Vr2xJ).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.

This overall effectiveness has seen the technology’s application in various segments, including but not limited to nicotine replacement, CBD, antivirals, epilepsy, human hormones, and PDE5 inhibitors. Lexaria’s venture into the hypertension sector acknowledges that over 114 million adults in the United States are at risk of damage caused by hypertension. In addition, the condition contributed to over 670,000 deaths within the country in 2020 alone (https://ibn.fm/FfRJX).

In this broadcast, Lexaria highlighted the progress it has made in its clinical studies and its success so far, ever since it began developing DehydraTECH in 2014. Furthermore, it expressed its confidence that its proposed solution will not only be safer but also a better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits.

Lexaria has made significant advancements in its clinical processes, amassing a growing body of evidence that strongly supports the use of its technology in hypertension therapeutics. This is not just a relief to millions of patients living with the condition but also a welcome addition for the company’s shareholders. In the communication, Lexaria noted that its valuation looks attractive with arguably significant upside. As a result, it looks to rub shoulders and gain attention from the likes of Pfizer Inc. (NYSE: PFE), Merc & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN), and Novartis AG (NYSE: NVS).

ReportLinker projects that the global anti-hypertensive drugs market will be valued at $27.81 billion by 2025, up from $24.17 billion in 2020, representing a compound annual growth rate (“CAGR”) of 0.8% (https://ibn.fm/VvUtZ). For comparison, each year, the United States spends an average of $131 billion in hypertension costs, with figures expected to go up, particularly given the low awareness of anti-hypertensive drugs amongst the population.

Lexaria is optimistic that with its DehydraTECH technology, hypertension treatment will not only be more accessible but also more efficient and effective, ultimately allowing for a better quality of life for patients and a healthier, more productive population.

The company is currently focusing on human clinical studies to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment. In addition, it is inching closer to approval by the United States Food and Drug Administration (“FDA”), having received positive feedback from the institution on its DehydraTECH-CBD proposals earlier this month (https://ibn.fm/8Mnmx).

Lexaria’s management still maintains late 2022/early 2023 for its Investigational New Drug (“IND”) application with the FDA and remains confident that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html